推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-34243363

chinasupport@letpub.com

登录 注册 新注册优惠

ANTI-CANCER DRUGS

2024年6月最新影响因子数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎点击此处反馈给我们。

按期刊名首写字母查看 ANTI-CANCER DRU最新评论:请问接收后多久 proof 的呀 (2024-10-24)


期刊名:   ISSN:   研究方向:   影响因子: -   SCI收录:
大类学科:   小类学科:   中国科学院分区:   是否OA期刊:   结果排序:
 
同行评审状态查询 Manuscript Number * Last Name * First Name * 出版社 * 查 询 重 置

按研究方向查看:


ANTI-CANCER DRUGS期刊基本信息Hello,您是该期刊的第54916位访客


基本信息 登录收藏
期刊名字ANTI-CANCER DRUGSANTI-CANCER DRUGS

ANTI-CANCER DRUG
(此期刊被最新的JCR期刊SCIE收录)

LetPub评分
5.7
54人评分
我要评分

声誉
6.6

影响力
4.4

速度
8.7

期刊ISSN0959-4973
微信扫码收藏此期刊
E-ISSN1473-5741
2023-2024最新影响因子
(数据来源于搜索引擎)
1.8 点击查看影响因子趋势图
实时影响因子 截止2024年10月29日:1.674
2023-2024自引率0.00%点击查看自引率趋势图
五年影响因子1.9
JCI期刊引文指标 0.63
h-index 88
CiteScore
2024年最新版
CiteScoreSJRSNIPCiteScore排名
3.800.4760.360
学科分区排名百分位
大类:Medicine
小类:Pharmacology (medical)
Q2129 / 272
大类:Medicine
小类:Oncology
Q3218 / 404
大类:Medicine
小类:Pharmacology
Q3181 / 313
大类:Medicine
小类:Cancer Research
Q3161 / 230

期刊简介
Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.
期刊官方网站http://journals.lww.com/anti-cancerdrugs/pages/default.aspx
期刊投稿网址https://www.editorialmanager.com/ACD
期刊语言要求经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足ANTI-CANCER DRUGS的语言要求,还能让ANTI-CANCER DRUGS编辑和审稿人得到更好的审稿体验,让稿件最大限度地被ANTI-CANCER DRUGS编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢(2篇)
提交文稿
是否OA开放访问No
通讯方式LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, USA, PA, 19106-3621
出版商Lippincott Williams and Wilkins Ltd.
涉及的研究方向医学-药学
出版国家或地区UNITED STATES
出版语言English
出版周期Monthly
出版年份1990
年文章数 142点击查看年文章数趋势图
Gold OA文章占比18.89%
研究类文章占比:
文章 ÷(文章 + 综述)
86.62%
WOS期刊SCI分区
2023-2024年最新版
WOS分区等级:3区

按JIF指标学科分区收录子集JIF分区JIF排名JIF百分位
学科:ONCOLOGYSCIEQ3241/322
学科:PHARMACOLOGY & PHARMACYSCIEQ3240/354
按JCI指标学科分区收录子集JCI分区JCI排名JCI百分位
学科:ONCOLOGYSCIEQ3169/322
学科:PHARMACOLOGY & PHARMACYSCIEQ3190/354
中国科学院《国际期刊预警
名单(试行)》名单
2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:不在预警名单中

2020年12月发布的2020版:不在预警名单中
中国科学院SCI期刊分区
2023年12月最新升级版
点击查看中国科学院SCI期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 2区4区2区
ONCOLOGY
肿瘤学
3区3区4区
PHARMACOLOGY & PHARMACY
药学
1区4区4区
中国科学院SCI期刊分区
2022年12月升级版
大类学科小类学科Top期刊综述期刊
医学 4区4区4区
ONCOLOGY
肿瘤学
1区1区4区
PHARMACOLOGY & PHARMACY
药学
1区3区4区
中国科学院SCI期刊分区
2021年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学 3区4区2区
ONCOLOGY
肿瘤学
3区2区4区
PHARMACOLOGY & PHARMACY
药学
2区2区4区
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)
Scopus (CiteScore)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0959-4973%5BISSN%5D
平均审稿速度网友分享经验:
偏慢,4-8周
平均录用比例网友分享经验:
容易
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)后论文在ANTI-CANCER DRUGS顺利发表。
快看看作者怎么说吧:服务好评 论文致谢
期刊常用信息链接
同领域相关期刊 ANTI-CANCER DRUGS期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 ANTI-CANCER DRUGS中国科学院SCI期刊分区趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
ANTI-CANCER DRUGS上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 中国科学院分区趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发文
  • 中国科学院分区相关期刊
  • 同类著名期刊名称 h-index CiteScore
    PHARMACOLOGICAL REVIEWS21034.70
    DRUG RESISTANCE UPDATES10026.20
    ADVANCED DRUG DELIVERY REVIEWS27828.10
    TRENDS IN PHARMACOLOGICAL SCIENCES20123.90
    PHARMACOLOGY & THERAPEUTICS18023.00
    MEDICINAL RESEARCH REVIEWS11929.30
    PHARMACOLOGICAL RESEARCH11818.70
    ARCHIVES OF PHARMACAL RESEARCH7513.40
    BIOMEDICINE & PHARMACOTHERAPY7811.90
    BRITISH JOURNAL OF PHARMACOLOGY19015.40
    中国科学院SCI期刊分区同大类学科的热搜期刊 浏览次数
    MEDICINE677700
    BIOMATERIALS567285
    BIOMEDICINE & PHARMACOTHERAPY552018
    Frontiers in Pharmacology515786
    Journal of Materials Chemistry B506974
    Frontiers in Immunology492571
    COMPUTERS IN BIOLOGY AND MEDICINE474436
    JOURNAL OF ETHNOPHARMACOLOGY466711
    COLLOIDS AND SURFACES B-BIOINTERFACES438831
    Frontiers in Oncology436521
  •  

    ANTI-CANCER DRUGS ANTI-CANCER DRUGS
    我来预测明年:
    稳步上升 表现平稳 逐渐下降  刷新
  •  

     
  •  

     
  •  

     
  • 中国学者近期发表的论文
    1.MiR-302c-5p affects the stemness and cisplatin resistance of nasopharyngeal carcinoma cells by regulating HSP90AA1

    Author: Zhou, Xiangqi; Zheng, Le; Zeng, Chunya; Wu, Yangjie; Tang, Xiyang; Zhu, Yuan; Tang, Sanyuan
    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. 135-143. DOI: 10.1097/CAD.0000000000001392
        PubMed      DOI
    2.Purvalanol A induces apoptosis and reverses cisplatin resistance in ovarian cancer

    Author: Zhang, Xiaoyi; Hong, Shasha; Yang, Jiang; Liu, Jingchun; Wang, Ying; Peng, Jiaxin; Wang, Haoyu; Hong, Li
    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. 29-43. DOI: 10.1097/CAD.0000000000001339
        PubMed      DOI
    3.Hsa_circ_0007380 silencing restrains the growth and enhances radiosensitivity in esophagus cancer by miR-644a/Spindlin 1 axis

    Author: Yu, Weihui; Ning, Ke; Xiao, Jincheng; Bai, Qiwen; Guo, Chenyang
    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. 166-177. DOI: 10.1097/CAD.0000000000001375
        PubMed      DOI
    4.Circ-ABCC4 contributes to prostate cancer progression and radioresistance by mediating miR-1253/SOX4 cascade

    Author: Yu, Tao; Du, Hong; Sun, Changhai
    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. 155-165. DOI: 10.1097/CAD.0000000000001361
        PubMed      DOI
    5.Circ_0058608 contributes to the progression and taxol resistance of non-small cell lung cancer by sponging miR-1299 to upregulate GBP1

    Author: Xuan, Xianglan; Wang, Zhiguang; Wang, Yayan
    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. 103-114. DOI: 10.1097/CAD.0000000000001346
        PubMed      DOI
    6.LOC554202 contributes to chordoma progression by sponging miR-377-3p and up-regulating SMAD3

    Author: Xu, Guang; Liu, Jingnan; He, Jun; He, Haibo; Su, Xiaotao; Gui, Qianhuan
    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. 15-28. DOI: 10.1097/CAD.0000000000001327
        PubMed      DOI
    7.GATA3 positively regulates PAR1 to facilitate in vitro disease progression and decrease cisplatin sensitivity in neuroblastoma via inhibiting the hippo pathway

    Author: Wang, Jing; Dai, Wang; Zhang, Ming
    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. 57-72. DOI: 10.1097/CAD.0000000000001341
        PubMed      DOI
    8.Herpesvirus entry mediator regulates the transduction of Tregs via STAT5/Foxp3 signaling pathway in ovarian cancer cells

    Author: Shan, Ying; Zhang, Beibei; Chen, Li; Zhang, Hu; Jiang, Cui; You, Qinghua; Li, Yanyi; Han, Hongyu; Zhu, Jianlong
    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. 73-80. DOI: 10.1097/CAD.0000000000001336
        PubMed      DOI
    9.Lung metastases after liver cancer resection cured by immunotherapy: case report and literature review

    Author: Ou, Limin; Lu, Guanhua; Cao, Mingrong; Hu, Min
    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. E1-E8. DOI: 10.1097/CAD.0000000000001371
        PubMed      DOI
    10.Application of long non-coding RNA RBAT1 in improving diagnosis and prognosis of ovarian carcinoma

    Author: Luo, Jie; Zhang, Yuqing; Zheng, Ting; Jing, Yongping; Cao, Rongyu; Wu, Minmin; Fan, Die; Tao, Ying; Zhao, Mandan
    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. 9-14. DOI: 10.1097/CAD.0000000000001315
        PubMed      DOI
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144873.20
    NATURE REVIEWS DRUG DISCOVERY289137.40
    LANCET700148.10
    NEW ENGLAND JOURNAL OF MEDICINE933145.40
    BMJ-British Medical Journal019.90
    BMJ-British Medical Journal019.90
    Nature Reviews Clinical Oncology12799.40
    Nature Reviews Disease Primers4876.70
    NATURE REVIEWS CANCER396111.90
    NATURE REVIEWS IMMUNOLOGY35193.40
    同分区等级的其他期刊名称 h-index CiteScore
    Energy Material Advances013.80
    Journal of High Energy Astrophysics119.70
    VIEW012.60
    HARVARD BUSINESS REVIEW01.40
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE1086.90
    ACM Transactions on Intelligent Systems and Technology469.30
    Journal of the American Nutrition Association02.50
    TRANSACTIONS OF TIANJIN UNIVERSITY012.50
    Machine Intelligence Research06.70
    Molecular Biomedicine06.30
以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分:

同领域作者分享投稿经验:共180


    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2024 中国: LetPub上海    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)

    增值电信业务经营许可证:沪B2-20211595    网络文化经营许可证:沪网文[2023]2004-152号

    礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室